Covered recipient · General Payments record
KELLEY WILSON
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$717.46
3 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $661.54 | 2 |
| Food and Beverage | $55.92 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $661.54 | 2 |
| Merck Sharp & Dohme LLC | $55.92 | 1 |
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KELLEY WILSON
NPI 1932398757 · CMS profile ID 224261
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
3 matching records · $717.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–3 of 3.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.92 | 12/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238330943 | CMS |
| Eli Lilly and Company | $364.90 | 10/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186706789 | CMS |
| Eli Lilly and Company | $296.64 | 10/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186713263 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,698,890.20 | 111 |
| PY2024 | Principal investigator | $3,248,583.50 | 103 |
| PY2023 | Recipient | $1,039.86 | 1 |
| PY2023 | Principal investigator | $1,084,081.62 | 189 |
| PY2022 | Recipient | $1,428.00 | 1 |
| PY2022 | Principal investigator | $532,395.28 | 190 |
| PY2021 | Recipient | $1,678.03 | 1 |
| PY2021 | Principal investigator | $1,711,588.07 | 233 |
| PY2020 | Principal investigator | $1,081,919.61 | 115 |
| PY2019 | Principal investigator | $698,002.09 | 160 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
190 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 12/29/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306939 |
| Principal investigator 1 | Incyte Corporation | $7,188.36 | 12/28/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040876425 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $1,260.00 | 12/21/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051511419 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $10,000.00 | 12/12/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051510943 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $170.00 | 12/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306859 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $300.00 | 12/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306869 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $525.00 | 12/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306879 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $2,992.29 | 12/07/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051510245 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 11/30/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306929 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $85.00 | 11/27/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306837 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $315.00 | 11/27/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306847 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $1,260.00 | 11/21/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051511207 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $678.90 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306719 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,030.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306731 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,030.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306741 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,262.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306751 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,262.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306761 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,073.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306771 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,073.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306783 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,073.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306793 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,149.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306803 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306815 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 11/15/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306827 |
| Principal investigator 1 | Incyte Corporation | $29.28 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961897 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961911 |
| Principal investigator 1 | Incyte Corporation | $29.28 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961923 |
| Principal investigator 1 | Incyte Corporation | $29.28 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961937 |
| Principal investigator 1 | Incyte Corporation | $29.28 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961949 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961961 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961971 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961983 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961997 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040962007 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040962021 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 11/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040962033 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $82.92 | 11/02/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307163 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $168.50 | 11/02/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307175 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 10/31/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306919 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $105.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306661 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $168.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306671 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $204.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306681 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $212.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306689 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $280.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306699 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $882.00 | 10/18/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306709 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $63.34 | 10/15/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306971 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,891.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306439 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,891.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306451 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,891.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306461 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,030.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306471 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,030.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306483 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,262.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306491 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,073.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306503 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,420.40 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306513 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,149.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306525 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,149.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306535 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,149.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306545 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,149.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306557 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306567 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306577 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306587 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306599 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,520.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306611 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,833.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306621 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,833.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306631 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,833.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306641 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $11,833.00 | 10/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306651 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.84 | 10/11/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306961 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,400.00 | 10/04/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306429 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $22.67 | 10/03/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051510985 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $69.10 | 10/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307131 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $69.10 | 10/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307143 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $82.92 | 10/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307153 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 09/29/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306909 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $105.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306363 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $255.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306375 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $716.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306385 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,250.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306399 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,150.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306409 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,360.00 | 09/20/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306419 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $55,350.80 | 09/13/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306353 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.84 | 09/12/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306949 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15.62 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307041 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $23.16 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307051 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.54 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307061 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $33.84 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307071 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $41.46 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307081 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $50.90 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307091 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $96.74 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307101 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $110.56 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307111 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $168.50 | 09/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307121 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 08/31/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306899 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $425.00 | 08/23/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306333 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $504.00 | 08/23/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306343 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,616.00 | 08/14/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306309 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $85,453.45 | 08/14/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306321 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $10.18 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306981 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $27.64 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306991 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $46.32 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307001 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $50.90 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307011 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $55.28 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307021 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $69.10 | 08/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030307031 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $5.00 | 08/02/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306299 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 07/31/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306889 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $22.67 | 07/26/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | RD006263 | No dispute reported | 06/30/2026 | 1051509807 |
| Principal investigator 1 | PFIZER INC. | $1,692.90 | 07/22/2023 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1046241067 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $47,022.15 | 07/12/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030306289 |
| Principal investigator 1 | Incyte Corporation | $20.42 | 07/05/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961771 |
| Principal investigator 1 | Incyte Corporation | $37.53 | 07/05/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961783 |
| Principal investigator 1 | Incyte Corporation | $171.25 | 07/05/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961795 |
| Principal investigator 1 | Incyte Corporation | $175.40 | 07/05/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961807 |
| Principal investigator 1 | Incyte Corporation | $0.33 | 07/05/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040961823 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 06/30/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337813 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $770.00 | 06/26/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337781 |
| Principal investigator 1 | Incyte Corporation | $4,359.00 | 06/22/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875993 |
| Principal investigator 1 | Incyte Corporation | $3,098.20 | 06/16/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875919 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $29,941.15 | 06/09/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337775 |
| Principal investigator 1 | Incyte Corporation | $3,303.00 | 06/08/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875981 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $40.72 | 06/01/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337837 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $50.90 | 06/01/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337843 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $55.28 | 06/01/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337851 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $55.28 | 06/01/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337857 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 05/31/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337807 |
| Principal investigator 1 | Eli Lilly and Company | $49,242.00 | 05/30/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | No dispute reported | 06/30/2026 | 1038066475 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $750.00 | 05/12/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337751 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,250.00 | 05/12/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337757 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,997.00 | 05/12/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337763 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $37,420.50 | 05/12/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337769 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $975.00 | 05/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337727 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,600.00 | 05/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337733 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,000.00 | 05/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337739 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14,438.00 | 05/08/2023 | Non-covered Recipient Entity K2 Medical Research Tampa LLC | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337745 |
| Principal investigator 1 | Incyte Corporation | $47,947.58 | 05/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875969 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $69.10 | 05/03/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337831 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 04/28/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337801 |
| Principal investigator 1 | Eli Lilly and Company | $349,110.00 | 04/24/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1038104865 |
| Principal investigator 1 | PFIZER INC. | $1,692.90 | 04/22/2023 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1046022337 |
| Principal investigator 1 | Incyte Corporation | $803.00 | 04/06/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875957 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4.80 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337863 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6.60 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337869 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $10.18 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337877 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $10.18 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337883 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $12.00 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337889 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $13.82 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337895 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.84 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337901 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $23.16 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337907 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $27.64 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337913 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $27.64 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337919 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $33.84 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337925 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $41.46 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337933 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $78.10 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337939 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $337.00 | 04/05/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337945 |
| Principal investigator 1 | ABBVIE INC. | $8,910.00 | 04/04/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998376257 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 03/31/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337795 |
| Principal investigator 1 | Incyte Corporation | $13,256.35 | 03/29/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1040876053 |
| Principal investigator 1 | Amgen Inc. | $37,500.00 | 03/24/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH | P3 AD Adult Combo TCS | No dispute reported | 06/30/2026 | 1029653757 |
| Principal investigator 1 | PFIZER INC. | $3,311.65 | 03/24/2023 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1046283397 |
| Principal investigator 1 | Eli Lilly and Company | $1,108.90 | 03/16/2023 | Non-covered Recipient Entity K2 MEDICAL RESEARCH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1038104877 |
| Principal investigator 1 | Incyte Corporation | $1,125.00 | 03/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1040876041 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $70.00 | 02/28/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337789 |
| Principal investigator 2 | E.R. Squibb & Sons, L.L.C. | $16,046.54 | 02/15/2023 | Non-covered Recipient Entity Olympian Clinical Research | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | No dispute reported | 06/30/2026 | 1027488747 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $25.00 | 02/12/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337819 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $95.01 | 02/12/2023 | Non-covered Recipient Entity K2 Medical Research | A Phase 2/3 Randomized Double-blind Parallelgroup Placebo-controlled Flexible-dose Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults with Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1030337825 |
| Principal investigator 1 | Incyte Corporation | $360.00 | 02/09/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1040876029 |
| Recipient | Eli Lilly and Company | $1,039.86 | 02/08/2023 | Covered Recipient Physician | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | No dispute reported | 06/30/2026 | 1038063395 |
| Principal investigator 1 | Eli Lilly and Company | $15,933.73 | 02/02/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1038066469 |
| Principal investigator 1 | Incyte Corporation | $270.00 | 02/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875943 |
| Principal investigator 1 | Incyte Corporation | $2,304.00 | 02/02/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1040876017 |
| Principal investigator 1 | Incyte Corporation | $24.39 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799789 |
| Principal investigator 1 | Incyte Corporation | $71.47 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799801 |
| Principal investigator 1 | Incyte Corporation | $50.04 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799817 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799833 |
| Principal investigator 1 | Incyte Corporation | $1.08 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799865 |
| Principal investigator 1 | Incyte Corporation | $1.10 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799891 |
| Principal investigator 1 | Incyte Corporation | $75.54 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799951 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799967 |
| Principal investigator 1 | Incyte Corporation | $6,318.80 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875906 |
| Principal investigator 1 | Incyte Corporation | $1,510.00 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1040875931 |
| Principal investigator 1 | Incyte Corporation | $1,723.95 | 02/01/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1040876005 |
| Principal investigator 1 | PFIZER INC. | $1,922.40 | 01/21/2023 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1046350689 |
| Principal investigator 1 | Incyte Corporation | $7,237.00 | 01/18/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040939947 |
| Principal investigator 1 | ABBVIE INC. | $2,878.75 | 01/11/2023 | Non-covered Recipient Entity ACADEMIC ALLIANCE IN DERMATOLOGY | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998365323 |
| Principal investigator 1 | PFIZER INC. | $1,922.40 | 01/06/2023 | Non-covered Recipient Entity Academic Alliance in Dermatology dba Olympian Clinical Research | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1046350703 |
| Principal investigator 1 | Incyte Corporation | $2.16 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799849 |
| Principal investigator 1 | Incyte Corporation | $1.43 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799877 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799909 |
| Principal investigator 1 | Incyte Corporation | $50.36 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799919 |
| Principal investigator 1 | Incyte Corporation | $100.72 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799935 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799983 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040799999 |
| Principal investigator 1 | Incyte Corporation | $43.92 | 01/03/2023 | Non-covered Recipient Entity OLYMPIAN CLINICAL RESEARCH | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1040800017 |